Pharmasyntez

Ownership

Private

Employees

~3750

Therapeutic Areas

OncologyNephrologyInfectious Diseases

Stage

Commercial

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Small molecules

Pharmasyntez General Information

Pharmasyntez is one of Russia's leading pharmaceutical companies with a focus on socially important drugs. Their new drug Vamotinib for chronic myeloid leukemia is currently in Phase III clinical trials, showing high efficacy and a favorable safety profile[8].

Contact Information

Website

https://pharmasyntez.com/en/

Primary Industry

Biotech

Corporate Office

Irkutsk, Irkutsk Region
Russia

Drug Pipeline

perchlozone

Commercial

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 2

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 3

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

For full access to Pharmasyntez's pipeline data

Book a demo

Key Partnerships

Baxter, SIBUR, Gamaleya National Research Institute of Epidemiology and Microbiology

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Pharmasyntez Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view Pharmasyntez's complete valuation and funding history, request access »

Pharmasyntez

Pharmasyntez General Information

Contact Information

Drug Pipeline

Key Partnerships

Pharmasyntez Funding

Interested in comprehensive profile data?

Pharmasyntez Financial Metrics